UA80270C2 - Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid - Google Patents

Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid Download PDF

Info

Publication number: UA80270C2
Authority: UA; Ukraine
Prior art keywords: chlorophenyl; dichloro; dodecanoic acid; croscarmellose sodium; group
Prior art date: 2002-01-16

Application number

UA20040806795A

Other languages

English (en)

Ukrainian (uk)

Inventor

Hiroyuki Kawashima

Yasuo Shinoda

Toshio Inagi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-16

Filing date

2003-01-15

Publication date

2007-09-10

2003-01-15 Application filed filed Critical

2007-09-10 Publication of UA80270C2 publication Critical patent/UA80270C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 26
GPCJDSXBRMKASP-UHFFFAOYSA-N 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid Chemical compound OC(=O)C(Cl)(Cl)CCCCCCCCCCC1=CC=C(Cl)C=C1 GPCJDSXBRMKASP-UHFFFAOYSA-N 0.000 title claims abstract description 24
150000002148 esters Chemical class 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 18
239000000126 substance Substances 0.000 claims abstract description 17
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 28
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 28
229920002785 Croscarmellose sodium Polymers 0.000 claims description 27
229960001681 croscarmellose sodium Drugs 0.000 claims description 27
239000008194 pharmaceutical composition Substances 0.000 claims description 15
238000000034 method Methods 0.000 claims description 13
238000002156 mixing Methods 0.000 claims description 6
239000012535 impurity Substances 0.000 claims description 4
239000003381 stabilizer Substances 0.000 claims description 2
230000000087 stabilizing effect Effects 0.000 claims description 2
238000012876 topography Methods 0.000 claims 1
239000011734 sodium Substances 0.000 abstract description 5
229910052708 sodium Inorganic materials 0.000 abstract description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 3
239000003826 tablet Substances 0.000 description 24
230000000052 comparative effect Effects 0.000 description 23
239000002775 capsule Substances 0.000 description 17
239000007884 disintegrant Substances 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
QZQFJPRNYPFYID-UHFFFAOYSA-M sodium;2,2-dichloro-12-(4-chlorophenyl)dodecanoate Chemical compound [Na+].[O-]C(=O)C(Cl)(Cl)CCCCCCCCCCC1=CC=C(Cl)C=C1 QZQFJPRNYPFYID-UHFFFAOYSA-M 0.000 description 8
238000003860 storage Methods 0.000 description 8
239000011230 binding agent Substances 0.000 description 6
229920002261 Corn starch Polymers 0.000 description 5
239000008120 corn starch Substances 0.000 description 5
229940099112 cornstarch Drugs 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
150000001875 compounds Chemical class 0.000 description 4
239000003814 drug Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000011521 glass Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
-1 alkali metal salts Chemical class 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
IBKRMNMQFADAEY-UHFFFAOYSA-N ClC(C)(CCCCCCCCCCC1=CC=C(C=C1)Cl)Cl Chemical compound ClC(C)(CCCCCCCCCCC1=CC=C(C=C1)Cl)Cl IBKRMNMQFADAEY-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229950008138 carmellose Drugs 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000004898 kneading Methods 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
238000003825 pressing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
239000008213 purified water Substances 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA20040806795A 2002-01-16 2003-01-15 Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid UA80270C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002007022		2002-01-16
PCT/JP2003/000251 WO2003059337A1 (fr)	2002-01-16	2003-01-15	Composition medicinale renfermant de l'acide 2,2-dichloro-12-(4-chlorophenyl) dodecanoique

Publications (1)

Publication Number	Publication Date
UA80270C2 true UA80270C2 (en)	2007-09-10

Family

ID=19191302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040806795A UA80270C2 (en)	2002-01-16	2003-01-15	Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid

Country Status (20)

Country	Link
US (1)	US20060051410A1 (fr)
EP (1)	EP1473033A1 (fr)
JP (1)	JPWO2003059337A1 (fr)
KR (1)	KR20040090975A (fr)
CN (1)	CN1259909C (fr)
AU (1)	AU2003201879B2 (fr)
BR (1)	BR0307172A (fr)
CA (1)	CA2474014A1 (fr)
EA (1)	EA007650B1 (fr)
HR (1)	HRP20040718A2 (fr)
IL (1)	IL162880A0 (fr)
IS (1)	IS7340A (fr)
MX (1)	MXPA04006977A (fr)
NO (1)	NO20043376L (fr)
NZ (1)	NZ534471A (fr)
PL (1)	PL373035A1 (fr)
TW (1)	TWI252755B (fr)
UA (1)	UA80270C2 (fr)
WO (1)	WO2003059337A1 (fr)
ZA (1)	ZA200406453B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY132415A (en) *	2003-05-23	2007-10-31	Kowa Co	Carboxylic compound and medicine comprising the same
WO2005117853A1 (fr) *	2004-06-01	2005-12-15	Kowa Co., Ltd.	Agent thérapeutique pour l'hyperlipémie et agent thérapeutique pour le diabète
EP1772149A1 (fr) *	2004-07-27	2007-04-11	Kowa Company. Ltd.	Médicament pour la prévention ou le traitement du diabète

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3586471B2 (ja) *	1991-06-25	2004-11-10	三菱ウェルファーマ株式会社	トラセミド含有医薬組成物
CA2100836C (fr) *	1993-07-19	1998-02-03	Bernard Charles Sherman	Composition pharmaceutique
DE4439947A1 (de) *	1994-11-09	1996-05-15	Boehringer Mannheim Gmbh	2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GT200100039A (es) *	2000-03-16	2001-12-31	Pfizer	Inhibidor de la glucogeno fosforilasa.

2003
- 2003-01-15 TW TW092100808A patent/TWI252755B/zh not_active IP Right Cessation
- 2003-01-15 UA UA20040806795A patent/UA80270C2/uk unknown
- 2003-01-15 EP EP03700558A patent/EP1473033A1/fr not_active Withdrawn
- 2003-01-15 BR BR0307172-3A patent/BR0307172A/pt not_active IP Right Cessation
- 2003-01-15 JP JP2003559500A patent/JPWO2003059337A1/ja not_active Withdrawn
- 2003-01-15 CA CA002474014A patent/CA2474014A1/fr not_active Abandoned
- 2003-01-15 AU AU2003201879A patent/AU2003201879B2/en not_active Expired - Fee Related
- 2003-01-15 CN CNB038019930A patent/CN1259909C/zh not_active Expired - Fee Related
- 2003-01-15 EA EA200400954A patent/EA007650B1/ru not_active IP Right Cessation
- 2003-01-15 MX MXPA04006977A patent/MXPA04006977A/es not_active Application Discontinuation
- 2003-01-15 NZ NZ534471A patent/NZ534471A/en unknown
- 2003-01-15 IL IL16288003A patent/IL162880A0/xx unknown
- 2003-01-15 WO PCT/JP2003/000251 patent/WO2003059337A1/fr active IP Right Grant
- 2003-01-15 PL PL03373035A patent/PL373035A1/xx unknown
- 2003-01-15 KR KR10-2004-7010955A patent/KR20040090975A/ko not_active Application Discontinuation
- 2003-01-15 US US10/500,463 patent/US20060051410A1/en not_active Abandoned
2004
- 2004-06-30 IS IS7340A patent/IS7340A/is unknown
- 2004-08-06 HR HRP20040718 patent/HRP20040718A2/xx not_active Application Discontinuation
- 2004-08-13 ZA ZA200406453A patent/ZA200406453B/en unknown
- 2004-08-13 NO NO20043376A patent/NO20043376L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1612730A (zh)	2005-05-04
HRP20040718A2 (en)	2004-12-31
IL162880A0 (en)	2005-11-20
CA2474014A1 (fr)	2003-07-24
PL373035A1 (en)	2005-08-08
EA200400954A1 (ru)	2004-12-30
ZA200406453B (en)	2006-06-28
KR20040090975A (ko)	2004-10-27
AU2003201879B2 (en)	2007-09-13
IS7340A (is)	2004-06-30
TWI252755B (en)	2006-04-11
WO2003059337A1 (fr)	2003-07-24
EA007650B1 (ru)	2006-12-29
US20060051410A1 (en)	2006-03-09
CN1259909C (zh)	2006-06-21
MXPA04006977A (es)	2005-04-19
TW200302079A (en)	2003-08-01
BR0307172A (pt)	2004-11-03
EP1473033A1 (fr)	2004-11-03
JPWO2003059337A1 (ja)	2005-05-19
NZ534471A (en)	2005-08-26
NO20043376L (no)	2004-08-13
AU2003201879A1 (en)	2003-07-30

Publication	Publication Date	Title
KR101786843B1 (ko)	2017-10-18	지질 저하제를 포함하는 제제
IE61173B1 (en)	1994-10-05	Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations
US8187635B2 (en)	2012-05-29	Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
EP2514422B1 (fr)	2016-08-10	Préparation du teneligliptine à élution stabilisée
UA73316C2 (uk)	2005-07-15	Фармацевтичний засіб, що містить похідну бензаміду як активний інгредієнт
KR100594606B1 (ko)	2006-06-30	속방성 경구 의약품 조성물
JP2012096998A (ja)	2012-05-24	安定なカプセル製剤及びその製造方法
UA80270C2 (en)	2007-09-10	Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid
JPH1121236A (ja)	1999-01-26	ロキソプロフェン・ナトリウム固形製剤
CN112741827B (zh)	2022-07-08	氨己烯酸固体制剂及其制备方法
JPWO2014013928A1 (ja)	2016-06-30	安定化された内服用固形製剤
JP7355846B2 (ja)	2023-10-03	固形製剤
JP2020183382A (ja)	2020-11-12	フィンゴリモド塩酸塩含有製剤及びフィンゴリモド塩酸塩含有製剤の製造方法
JP2001354566A (ja)	2001-12-25	ニセルゴリンの錠剤
JP2020083887A (ja)	2020-06-04	アジルサルタンを含有する錠剤
JP2019089758A (ja)	2019-06-13	セレコキシブ含有錠剤における溶出性の改善方法
WO2023107082A1 (fr)	2023-06-15	Comprimé pelliculé de saxagliptine et d'au moins un antioxydant traité par granulation humide
TW202227047A (zh)	2022-07-16	甲狀腺荷爾蒙的製劑化方法
TR2021019469A1 (tr)	2023-06-21	A film coated tablet of saxagliptin and at least one antioxidant processed with wet granulation
CN112972395A (zh)	2021-06-18	胶囊制剂及其制备方法和应用
JP2003119121A (ja)	2003-04-23	錠剤の製造方法
JP2004091373A (ja)	2004-03-25	分解に対する安定性及び含量均一性に優れたメシル酸ペルゴリド含有製剤
JPH11302196A (ja)	1999-11-02	アズレンスルホン酸ナトリウム含有製剤
RU2009103661A (ru)	2010-08-20	Стабильная фармацевтическая композиция, содержащая комбинацию влагочувствительного лекарственного вещества и второго лекарственного вещества, и способ ее приготовления
JP2011213606A (ja)	2011-10-27	ドネペジルを含有する固形製剤の製造方法